# Electra Therapeutics

Source: https://onco.cc/companies/electra-therapeutics/  
OnCo record `electra-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A US company making antibodies against SIRP proteins to remove overactive immune cells. Its lead drug is mainly for a dangerous inflammatory condition called sHLH, and it is also in an early trial for T-cell and NK-cell blood cancers that have come back.

## Summary

Electra Therapeutics develops antibodies directed at signal regulatory proteins (SIRP) that it says selectively deplete activated, disease-driving immune cells. Its lead antibody, ipsoprubart (ELA026), binds SIRP-alpha and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells. It is in a registrational Phase 2/3 programme as first-line treatment for secondary haemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory condition whose largest subtype, the company says, is malignancy-associated HLH, and in a Phase 1 trial in relapsed or refractory T-cell and NK-cell malignancies (NCT07465835, recruiting since February 2026). A second antibody, ELA822, is aimed at immune-mediated diseases. The IPO prospectus states the company was incorporated in Delaware in October 2018 as a wholly owned subsidiary of Star Therapeutics. Its Form 8-K reports that the IPO closed on 21 September 2026 at $15.00 a share for gross proceeds of about $350.0 million, with the stock on the Nasdaq Global Select Market under ETRA.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Electra Therapeutics, Inc.; Electra Therapeutics Inc.
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://electra-therapeutics.com/
- Ticker: NASDAQ: ETRA

## Notes

- Cancer ids left empty: the trial condition is 'T Cell Malignancies' without a named subtype, and sHLH is not a cancer.
- NCT07465835 (Phase 1, T/NK cell malignancies) and NCT05416307 (Phase 2/3, sHLH) were confirmed through the ClinicalTrials.gov v2 API; neither is a trial record in OnCo yet.
- OrbiMed's portfolio page lists Electra with a first investment dated 02/09/2022; the prospectus names OrbiMed Private Investments VII as a holder with a board designee.

## Sources

- SEC: Electra Therapeutics Form S-1/A, September 2026: https://www.sec.gov/Archives/edgar/data/2088082/000119312526389755/d61940ds1a.htm
- Official website: https://electra-therapeutics.com/
- Pipeline page: https://electra-therapeutics.com/pipeline/
- Ipsoprubart page: https://electra-therapeutics.com/ipsoprubart/
- Form 8-K on IPO closing, 21 September 2026: https://www.sec.gov/Archives/edgar/data/2088082/000119312526396646/d185250d8k.htm
- IPO prospectus (424B4): https://www.sec.gov/Archives/edgar/data/2088082/000119312526395670/d61940d424b4.htm
- ClinicalTrials.gov NCT07465835: https://clinicaltrials.gov/study/NCT07465835
- RA Capital portfolio entry: https://www.racap.com/portfolio/electra-therapeutics
- OrbiMed portfolio: https://www.orbimed.com/portfolio/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [SIRPA](https://onco.cc/targets/sirpa/)
- drugs: [Ipsoprubart](https://onco.cc/drugs/ipsoprubart/)
- companies: [OrbiMed](https://onco.cc/companies/orbimed/), [RA Capital Management](https://onco.cc/companies/ra-capital/)
- trials: [A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)](https://onco.cc/trials/nct07465835/)

---
JSON: https://onco.cc/api/v1/entities/electra-therapeutics.json